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A Unified Approach to Access N-Acyl Sulfonamide Tethered
Peptide Conjugates
Nagamangala Ramachandra Sagar, Suram Durgamma, Chinthaginjala Srinivasulu,
Hosamani Basavaprabhu, and Vommina Venkata Sureshbabu*[a]
Herein we demonstrate a chemoselective reaction of Nβ-
protected amino alkyl sulfonyl azides with in situ generated Nα-
protected amino acid selenocarboxylates via step wise intra-
molecular cyclization followed by decomposition to obtain N-
acyl sulfonamide tethered peptidyl conjugates. The protocol
offers the synthesis of orthogonally protected N-acyl sulfona-
mide tethered peptidomimetics under simple and mild reaction
conditions employing commercially available amino acids in
presence of NaBH2Se3 as a selenating agent. Also, the synthesis
of N-acyl sulfonamide tethered amino acid and aryl conjugates
were accomplished as an extension of the above strategy.
Introduction
Over the last two decades, peptides, peptide conjugates and
peptidomimetics have moved to the fore front of research in
the areas of chemistry, biology and medicine.[1] Researchers are
increasingly becoming curious in these molecules due to their
inexhaustible potential to serve as molecules of choice for
multiple applications. In particular, the study on peptidomi-
metic molecules which function by the imitation of the
topological architecture of the peptide backbone but contain
non-native linkages in lieu of native peptide bond or include
tailor made amino acid like structures/amino acid derivatives
has been receiving tremendous attention.[2] The study on
peptide conjugates and peptide tethers are emerging as a vital
area as a derivative of peptide chemistry. Several new types of
peptide conjugates are being designed and assembled employ-
ing predominantly amino acids as starting compounds. In view
of this, our group designed and synthesized various un-natural
peptide tethers such as ureido,[3] thioureido,[4] selenoureido[5]
and guanidine[6] subunits. We now delineate our studies on the
synthesis of N-acylsulfonamide tethered peptide conjugates
under simple and mild conditions employing N-protected
amino acids as starting materials in few steps.
N-Acyl sulfonamides have significant importance in medic-
inal chemistry.[7] They find applications as linkers for anchoring
the solid support and in chemoselective ligation and bioconju-
gation reactions.[8] Also, they constitute an important class of
drugs such as therapeutic agents for Alzheimer’s disease,[9]
antibacterial inhibitors of tRNA synthetases,[10] antagonists for
angiotensin[11] and leuko-triene D4 receptors.[12] Conventional
approaches for N-acylation of sulfonamides rely on reaction of
sulfonamide with carboxylic acid by commonly used coupling
agents: 1,1’-carbonyldiimidazole (CDI)[13a] and 1-ethyl-3-(3-dime-
thylaminopropyl) carbodiimide (EDC).[13b] N,N’-Dicyclohexylcar-
bodiimide (DCC) has also been used as coupling agent to
obtain N-acyl sulfonamide derived nucleosides.[13c] Alternatively,
coupling of benzoyl chloride (acid chlorides)/ acid anhydrides
with mesylaniline derivatives in presence of base resulted N-
acyl-N-mesylaniline derivatives.[14] In addition, mixed anhydrides
have also been used to make N-acyl sulphonamides by
acylation of sulfonamides.[15] Katritzky employed N-acylbenzo-
triazoles for the acylation of acetazolamides.[16] Besides, syn-
thesis of N-acyl sulfonamides was demonstrated by acylation of
nitro pyridine sulfonamides using carboxylic acid anhydrides
under acidic conditions.[17] Furthermore, metal catalysts were
also employed to achieve N-acyl sulfonamides upon acylation
of methane sulfonamides.[18] However, majority of the methods
discussed above result in formation of diacylated byproducts
which was the major disadvantage.[14] Also, the harsh reaction
conditions, tedious work up procedures, long reaction times
and usage of expensive reagents prompted us to look for an
alternative strategy for the synthesis of the title molecules. In
addition, very few reports describe the synthesis of N-acyl
sulfonamide tethered peptide conjugates, which generally
involve the reaction of thioacids as acid activator counterpart
and sulfonyl azides as reacting partners.[19] Williams et. al have
explored However, synthesis, handling, storage, purification
and stability issues of thioacids lead the sulfo-click reaction less
utilized and also base is required prior to amidation.[19a]
Synthesis of only one example of N-acyl sulfonamide was
reported by Wu and Hu by reacting selenocarboxylate derived
from benzoic acid with p-tolylsulfonyl azide in one pot using
LiAlHSeH as selenating agent.[20a] The in situ generated seleno-
carboxylate has been found as a potential precursor for diverse
chemical reactions.[21a] Reich and Hondal reported the bio-
logical and chemical importance of selenolates as well as its
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comparision with sulfur analogues.[21b] Apart from medicinal
chemistry application, N-acyl sulfonamide moiety introduces
additional tetrahedral-type geometry at the peptide backbone
and such modification would favour the disruption of amyloi-
dogenic aggregation.
In continuation of our interest in the design and synthesis
of novel molecules, as an extension of our previous work
imides,[22] we tried to explore the synthesis of yet another new
class of urethane protected N-acyl sulfonamide tethered aryl as
well as peptidyl conjugates as an improved alternative
protocol. This was achieved by employing commercially
available amino acids and sulfonyl azides in presence of
NaBH2Se3 as selenating agent without the isolation of in situ
generated seleninate intermediate, which otherwise acts as an
activated acid counterpart.
Results and Discussion
Williams et al. have explored the stoichiometric coupling,
reactivity and mechanism of thio acid/ azide amidation in
detail. Having referred the reactivity of azides,,[19b,19c][24] in our
initial part of the study, as a representative reaction Cbz-Phe-
OH was converted to corresponding selenocarboxylate by
treating it with freshly prepared NaBH2Se3.
[22] The in situ
generated selenocarboxylate was then reacted with Fmoc-Val-
CH2SO2N3 (3a, 1.0 mmol) at room temperature. 3a was synthe-
sized as reported earlier by our group.[23] The reaction was
monitored by TLC till the consumption of sulfonylazide and
was found to complete in 2.5 h to afford the corresponding N-
acyl sulfonamide (4a) in 91% yield after column purification.
Table 1. Synthesis of orthogonally protected N-acyl sulfonamide tethered dipeptides
Entry Amino acid 1 Sulfonyl azide 3 Product 4 Yield a [%]
a 91
b 86
c 93
d 89
e 93
e* 92
f 90
aIsolated yield after column chromatography
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In one of the reports, to obtain N-acyl sulfonamide, DMF
was chosen over DCM as an alternative solvent by reasoning
partial solubility of sulfonyl azide.[8n] However, high boiling
point solvents are onerous to remove from reaction mixture
and so is DMF. Since THF was preused to obtain selenocarbox-
ylates, other solvents seemed redundant for further coupling
with sulfonyl azide. This prompted us to prefer THF as a solvent
as various sulfonyl azides were completely soluble.
Interestingly, orthogonally protected N-acyl sulfonamide
tethered dipeptides was obtained from the coupling of Nβ-
protected amino alkyl sulfonyl azides with in situ generated
amino acid selenocarboxylate in almost quantitative yield
(Table 1). The generality of protocol was demonstrated by
employing a series of simple and sterically hindered alkyl and
aryl side chains with urethane protectors Fmoc and Cbz.
The above strategy was further extended to peptides,
where in Nα-protected dipeptide acids were used as starting
materials to generate dipeptide derived selenocarboxylates
under established procedure. This in situ generated intermedi-
ate was made to react with benzene sulfonyl azide to form Nα-
protected dipeptide derived N-acyl sulfonamides in good yields
(Table 2).
The methodology was also extended to prepare a few
examples of N-acyl sulfonamide tethered amino acid and aryl
conjugates by treating Nα-protected amino acids with phenyl-,
tolyl- dansyl-, difluorobenzyl sulfonyl azides in presence of
NaBH2Se3 under the optimized conditions. Barlett et al have
explored NAS peptide conjugates in good yield.[24] However,
employed strategy is not suitable for acid sensitive functional
groups. To overcome this problem, we have synthesized tBu-
side chain protected serine and tyrosine based N-acyl sulfona-
mide wherein protector, tertiary butyl group was found
tolerant under the present reaction conditions. The respective
products were obtained in good yields (Table 3).
In additon, Nβ-protected amino alkyl sulfonyl azides was
treated with selenocarboxylates derived from coumarin-3- and
2-thiophene carboxylic acids to form corresponding N-acyl
sulfonamides with aryl ring at one end and Nα-protected amino
acid skeleton at the other end (Table 4).
To check the possible epimerization during the course of
the reaction, Fmoc-Ala-Ψ[NHSO2CH2]-Phg-(L)-Cbz (4e) and
Fmoc-Ala-Ψ[NHSO2CH2]-Phg-(D)-Cbz (4e*) were subjected to
racemization studies. The HPLC analyses of the diastereomeric
N-acyl sulfonamides 4e and 4e*, when injected separately,
showed the retention times of 23.35 min and 21.42 min,
respectively. However, intentionally mixed two compounds
showed distinct retention times of 23.00 min and 21.72 min
respectively. Also, optically pure Cbz-(L)-Phg-OH and Cbz-(D)-
Phg-OH was employed as substrates for the synthesis of
corresponding N-acyl sulfonamides through in situ generated
selenocarboxylates. In both these cases, p-tolylsulfonyl azide
was used as a standard reaction partner. HPLC analyses of 10g
and 10g* when injected separately, showed the retention
times of 15.72 min and 13.05 min, respectively. However
purposely mixed two compounds showed distinct retention
times of 15.59 min and 12.91 min respectively. Thus this study
infers that the present protocol is free from observable
racemization.
The mechanism involving in this reaction seems to operate
in a similar fashion as we observed in our previous work on
preparation of thioureidopeptidomimetics by reacting azides
and dithiocarbamates.[20b] Also, the similar reaction pathway
was illustrated by Manetsch and coworkers for sulfo-click
reaction of thioacids and sulfonyl azides.[19a] In the possible
mechanism, selenocarboxylate formed in situ by the selenation
of corresponding acid in presence of selenating agent reacts
with azide via stepwise linear coupling to form an intermediate
I. This later undergoes intramolecular cyclization to form a five
membered ring with 4-heteroatoms including three N-atoms
and one selenium atom. This on further decomposition
through retro-[3+2] reaction result in the expulsion of N2 and
Se to give desired N-acyl sulfonamide.
Table 2. Synthesis of Nα-protected dipeptide acid derived N-acyl sulfonamides.
Entry Peptide 5 Sulfonyl azide 7 Product 8 Yield a [%]
a 82
b 85
aIsolated yield after column chromatography
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Table 3. Synthesis of N-acyl sulfonamide tethered amino acid and aryl conjugates.
Entry Amino acid 1 Sulfonyl azide 9 Product 10 Yielda [%]
a 94
b 90
c 92
d 88
e 86
f 90
g 95
g* 94
aIsolated yield after column chromatography
Figure 1. Possible mechanism for N-acyl sulfonamide formation.
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Conclusions
We have demonstrated a straight forward approach for the
synthesis of orthogonally protected N-acyl sulfonamide teth-
ered dipeptides under mild reaction conditions employing
commercially available amino acids and sulfonyl azides medi-
ated by selenating agent without the isolation of active
intermediate, selenocarboxylate. The protocol was also ex-
tended to synthesize Nα-protected dipeptide acid derived acyl
sulfonamides bearing amide and N-acyl sulfonamide hybrid
tethers in the back bone. In addition, synthesis of N-acyl
sulfonamide tethered amino acid and aryl conjugates was also
accomplished. All the products were obtained in good yields
irrespective of nature of side chains including simple as well as
sterically hindered ones.
Supporting information summary
General procedure for the synthesis of N-acyl sulfonamides,
HRMS, 1H, 13CNMR spectra, and characterization data of all the
synthesized compounds (4a–4f, 8a,8b, 10a–10 g* and 13a,13b),
and RP-HPLC chromatograms with data are appended in the
supporting information.
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